Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Summary

The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol overall.

Timeline

Start

2021-07-07

Primary completion

2023-01-13

Completion

2023-01-13

Publications

• Wilson P, Elvey R, Mathieson A, Bower P, Gibson M, Vell T, Dixon S. Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders. BMJ Open. 2025 Feb 26;15(2):e083441. doi: 10.1136/bmjopen-2023-083441.
• Mathieson A, Elvey R, Wilson P. Development and application of a qualitative rapid analysis framework in a hybrid trial within primary care. BMJ Open. 2024 Jul 24;14(7):e076792. doi: 10.1136/bmjopen-2023-076792.

Drugs

Indications